Silence Therapeutics plc (SLN)

Silence Therapeutics Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	54.03	54.82	73.54	27.45	13.52
Short-Term Investments	0	16.33	0	10	20
Cash & Cash Equivalents	54.03	71.14	73.54	37.45	33.52
Cash Growth	-24.05%	-3.25%	96.37%	11.73%	26.30%
Receivables	0.23	0.92	0.33	29.31	0
Other Current Assets	26.76	24.63	12.47	9.64	3.95
Total Current Assets	81.02	96.69	86.33	76.4	37.47
Property, Plant & Equipment	1.81	2.2	1.94	1.13	0.61
Long-Term Investments	0.28	0.28	0.3	0.3	0.28
Goodwill and Intangibles	8.12	8.33	7.62	8.14	7.73
Other Long-Term Assets	2.58	0	0	0	0
Total Long-Term Assets	12.8	10.81	9.86	9.57	8.61
Total Assets	93.82	107.5	96.19	85.97	46.08
Accounts Payable	12.43	12.63	10.78	8.19	6.89
Deferred Revenue	64.07	72.35	76.75	68.38	17.99
Current Debt	0.18	0.45	0.14	0.34	0.29
Other Current Liabilities	-58.91	-63.49	-72.5	-51.34	-15.52
Total Current Liabilities	17.77	21.94	15.17	25.58	9.65
Long-Term Debt	0.09	0	0	0	0
Other Long-Term Liabilities	58.91	63.49	72.5	51.34	15.52
Total Long-Term Liabilities	59	63.49	72.5	51.34	15.52
Total Liabilities	76.77	85.43	87.67	76.91	25.17
Total Debt	0.27	0.45	0.14	0.34	0.29
Debt Growth	-39.01%	225.55%	-59.82%	18.82%	-
Retained Earnings	-304.61	-263.26	-222.97	-184.22	-152
Comprehensive Income	1.95	2.09	1.54	2.22	1.75
Shareholders' Equity	17.05	22.07	8.53	9.06	20.91
Net Cash / Debt	53.76	70.7	73.4	37.11	33.23
Net Cash / Debt Growth	-23.96%	-3.68%	97.80%	11.67%	25.22%
Working Capital	63.25	74.74	71.17	50.82	27.81
Book Value Per Share	0.44	0.61	0.28	0.35	0.80

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).